Ocera Therapeutics, Inc.
OCRX
OCRX was delisted on the 8th of December, 2017.
27 hedge funds and large institutions have $21.5M invested in Ocera Therapeutics, Inc. in 2015 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 12 increasing their positions, 3 reducing their positions, and 8 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 3
4% less capital invested
Capital invested by funds: $22.4M → $21.5M (-$870K)
16% less funds holding
Funds holding: 32 → 27 (-5)
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.92M |
| 2 |
TI
Turner Investments
Berwyn,
Pennsylvania
|
+$1.62M |
| 3 |
QF
QVT Financial
New York
|
+$625K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$181K |
| 5 |
Millennium Management
New York
|
+$125K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OPPM
Opus Point Partners Management
New York
|
-$709K |
| 2 |
JP Morgan Chase
New York
|
-$275K |
| 3 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$208K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$38K |
| 5 |
Morgan Stanley
New York
|
-$27K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $4K | – | – | – |
|
27
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $6 | – | – | – |
|
|
OPPM
28
Opus Point Partners Management
New York
| – | -$709K | -186,573 | Closed |
|
|
29
JP Morgan Chase
New York
| – | -$275K | -72,467 | Closed |
|
|
30
Citadel Advisors
Miami,
Florida
| – | -$38K | -10,082 | Closed |
|
|
31
Morgan Stanley
New York
| – | -$27K | -7,028 | Closed |
|
32
Citigroup
New York
| – | -$11K | -3,095 | Closed |
|
33
First Manhattan
New York
| – | -$3K | -1,000 | Closed |
|
|
TRCT
34
Tower Research Capital (TRC)
New York
| – | -$1K | -257 | Closed |
|
OCRX Hedge Fund Activity: Q3 2015 in Review
27 of the 3,583 institutional investors tracked by Wall St. Rank reported a position in Ocera Therapeutics, Inc. (OCRX) for Q3 2015, worth a combined $21.5M — down 3.9% from $22.4M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of OCRX and 3 opened new positions — a net loss of 5 holders — while 3 trimmed existing stakes and 12 added.
The largest buyer was Sphera Funds Management, opening a new position worth an estimated $1.92M. The largest seller was Opus Point Partners Management, exiting entirely with an estimated $709K sold.
- 27 institutional investors held Ocera Therapeutics, Inc. (OCRX) as of Q3 2015, down from 32 in Q2 2015.
- Funds reported $21.5M of Ocera Therapeutics, Inc. stock for Q3 2015, down 3.9% quarter-over-quarter.
- 3 funds opened new Ocera Therapeutics, Inc. positions in Q3 2015 and 8 closed out, a net change of -5 holders.
- The largest Ocera Therapeutics, Inc. buyer in Q3 2015 was Sphera Funds Management, an estimated $1.92M added.
- The largest Ocera Therapeutics, Inc. seller in Q3 2015 was Opus Point Partners Management, an estimated $709K sold.
Based on aggregated 13F filings for Q3 2015.